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Objective: The aim of our study was to evaluate the impact of recent clopidrogel use before off-pump coronary
artery bypass grafting on the postoperative risk of bleeding.
Methods: During the period January 2003 to December 2006, 1104 consecutive patients underwent off-pump
coronary artery bypass grafting. Patients were divided into two groups according to the recent use of clopidrogel
(within 7 days). We performed a propensity score to further adjust for differences between the patients with and
without recent use of clopidrogel.
Results: Mean age was 64  14 years and 87% were male. The clopidrogel group had a greater incidence of
patients in unstable condition, requiring emergency coronary bypass grafting, and with a high EuroSCORE. Pro-
pensity score analysis selected 88 patients with and 176 without recent use of clopidrogel. By propensity score,
the clopidrogel group had higher requirements for fresh frozen plasma units (18.1% vs 8.5%; P¼ .02), reopera-
tion owing to bleeding (5.6% vs 0.5%; P ¼ .009), and higher need for postoperative mechanical ventilation
(4% vs 10%; P ¼ .04), whereas mortality and length of stay were similar between groups.
Conclusion: Recent use of clopidogrel before off-pump coronary artery bypass grafting is associated with greater
risk for bleeding with similar mortality rate.
Vaccarino et al Acquired Cardiovascular DiseaseCurrently, a percutaneous approach is preferred for patients
with high-risk acute coronary syndromes. The percutaneous
approach is favored particularly because of improvements in
stent design and the possibility of exerting a strong platelet
inhibition by dual antiplatelet therapy. During coronary
angioplasty, oral administration of clopidogrel, a direct
adenosine diphosphate receptor antagonist, has reduced
the likelihood of in-stent thrombosis from 18% to 24% to
values lower than 2%.1,2 Thus, dual antiplatelet therapy (as-
pirin plus clopidogrel) is well tolerated and constitutes the
standard oral prophylaxis for stent thrombosis.3-6
The multicenter randomized clinical trials CAPRIE* and
CUREy have established the basis for standardization of clo-
pidogrel administration to all patients with acute coronary
syndromes.7,8 Owing to the aforementioned reasons, many
patients receive clopidogrel before cardiac catheteriza-
tion.4-9
Several investigators have reported an increase in surgical
bleeding risk owing to clopidogrel administration before
coronary artery bypass grafting (CABG). Furthermore, the
irreversible antiplatelet activity of clopidogrel combined
with the known deleterious effects of extracorporeal circula-
tion on the coagulation cascade further increases the likeli-
hood of cardiac reoperation up to 10 times.10-14
Off-pump surgical revascularization (OPCABG) is a safe
technique and reduces bleeding risk when compared with
on-pump surgery.15-21 Nevertheless, clopidogrel administra-
tion before OPCABG could potentially reduce its homeo-
static advantage.22-27
Therefore, the aim of our study was to determine the im-
pact of clopidogrel administration before OPCABG on the
risk of bleeding and subsequent need for cardiac reoperation.
PATIENTS AND METHODS
From January 2003 to December 2006, we prospectively included 1104
consecutive patients who underwent OPCABG. Patients were excluded
from the analysis if they had significant valvular heart disease, congenital
heart disease, ascending aortic disease, or if surgery was combined with ca-
rotid revascularization. During the study period, only 46 (4%) patients un-
derwent on-pump CABG. We divided the population into two groups
according to the administration of clopidogrel within 7 days before cardiac
surgery: (1) clopidogrel group and (2) control group. All patients from both
groups received aspirin before the surgical procedure and an intraoperative
intravenous bolus of unfractionated heparin dosage of 300 IU/kg with ad-
justed heparin doses to maintain activated clotting times greater than 450
seconds. During all procedures, heparin reversal was performed with prot-
amine (activated clotting time goal<110 seconds). It has been customary
in our institution to refrain from administering hemostatic drugs such as
aprotinin or aminocaproic acid. Several surgical studies have reported an
enhanced risk of graft thrombosis with the use of aprotinin.
Operative Technique
All surgical procedures were performed by the same surgical team.
OPCABG was performed through a standard median sternotomy, the
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CABG ¼ coronary artery bypass grafting
ITA ¼ internal thoracic artery
OPCABG ¼ off-pump coronary artery bypass
grafting
pericardial cavity was opened wide, and deep pericardial sutures were
placed for traction. The internal thoracic artery (ITA) was harvested by
a skeletonized technique. The in situ left ITA was used for the left anterior
descending coronary artery. Allen’s test was routinely performed before
harvesting the radial artery, and capillary refilling of the palm within 10 sec-
onds was judged as negative. Whenever a saphenous vein graft was used, it
was extracted with minimally invasive technique as previously described.28
Proximal free right ITA anastomosis and radial artery graft were
performed according to the technique of Tector and Schmahl.29 Right
ITA, radial artery, and saphenous vein grafts were used for revascularization
of the lateral and inferior myocardial territories. Distal anastomoses were
performed while the heart was stabilized with an Octopus II/III stabilizer
(Medtronic, Minneapolis, Minn). A cell salvage device was not used during
the operation in any patients.
Indications for cardiac reoperation were as follows: (1) excessive
bleeding and/or (2) cardiac tamponade. Excessive postoperative bleeding
was defined as more than 300 mL during the first hour, more than 250
mL during the second hour, more than 200 mL during the third hour, or
a total of 1000 mL or more during the first 6 hours.
Blood and blood products transfusions (red cells, platelets, plasma, and
cryoprecipitate) were counted by units. Postoperative need for transfusion
was defined by the following criteria: (1) reduction in hematocrit to 21%
or less and (2) hematocrit between 21% and 30% in the context of active
bleeding, hypovolemia, hypoxemia, or neurologic symptoms.
We analyzed the following baseline variables that have been previously
reported as predictors of postoperative bleeding19-23: age, gender, presence
of chronic systemic hypertension, diabetes mellitus, renal insufficiency, he-
matocrit and creatinine levels, EuroSCORE, prior acute myocardial infarc-
tion, CABG, presence of heart failure, current clinical presentation, left
ventricular ejection fraction, carotid or peripheral vascular disease, and
chronic pulmonary obstructive disease.
Major adverse cardiovascular events were defined as the occurrence of
one of the following: death, stroke, or myocardial infarction.
Statistical Analysis
Continuous variables are expressed as mean values ( standard devia-
tion) and compared by the Student t test. Categorical variables are expressed
as percentages and compared by the c2 statistic or Fisher’s exact test.
We performed two separate analyses regarding the relationship between
clopidogrel use and bleeding complications. In the first analysis, we in-
cluded the entire population (n¼ 1104) and compared both groups’ clinical
results. For the second analysis, in an attempt to control for baseline differ-
ences between the two groups, we performed a propensity score that would
predict the use of clopidogrel. Only the variables that differed between the
two unmatched groups (n ¼ 1104) were included to generate a propensity
score to predict perioperative clopidrogel administration by a logistic re-
gression analysis. All patients, regardless of their clopidrogel status, re-
ceived a propensity score. All scores were sorted numerically. Whenever
possible, patients with similar scores were matched in a 1:2 clopidrogel/con-
trol fashion. We obtained 88 comparisons (n ¼ 88 in the clopidrogel group
and n ¼ 166 in the control group).
The use of a propensity score attempts to reproduce the baseline similar-
ities of a randomized population; however, it has inherent limitations.30
The statistical analysis was performed with Stata 9.1 software (StataCorp,
College Station, Tex).
RESULTS
From a total of 1104 patients included in the analysis, 123
(11%) patients received clopidogrel within 7 days before the
procedure (clopidogrel group) and 981 did not (control
group). Baseline demographics of both surgical groups are
shown in Table I. Age and gender proportions were similar
between the two groups. As expected, the percentage of pa-
tients undergoing cardiac catheterization during the index
hospitalization was significantly higher in the clopidogrel
group (73% vs 33%;P<.0001). In addition, clinical presen-
tation with an acute coronary syndrome was more frequent
than in the control group (73% vs 63.4%; P< .05). Lower
hematocrit (40.9%  4.2% vs 38%  43%; P ¼ .0005)
and creatinine (1.11  0.29 mg/dL vs 1.19  0.40 mg/dL;
P ¼ .02) values were observed in the clopidogrel group.
Clinical outcome data are detailed in Table II. There was
a trend toward more renal insufficiency (4% vs 1.7%;
P ¼ .08) and a nonsignificant difference in the need for
hemodyalysis (1.6% vs 0.6%; P ¼ .2) in the clopidogrel
group. Furthermore, the clopidogrel group was also associ-
ated with greater need for assisted mechanical ventilation
(11.3% vs 2.5%; P ¼ .0001) and transfusion (57.7% vs
45.9%; P ¼ .02) than the controls. The rates of reoperation
(1.7% vs 1.4%; P ¼ .03) and major adverse cardiac events
(17.07% vs 7.24%; P¼ .0001) were higher in the clopidog-
rel group. The median hospitalization lengths of stay were
8 days (interquartile ratio 25–75: 5–10) and 5 days (inter-
quartile ratio 25–75: 4–7) for the clopidogrel and control
groups, respectively (P ¼ .0001). Overall 30-day mortality
rate was 2.9%; this rate was 4.8% (n¼ 6) in the clopidogrel
group and 2.7% (n ¼ 27) for the controls (P ¼ .1).
Baseline demographics and clinical outcomes in the two
matched groups are summarized in Tables III and IV. By
propensity score, clinical results of the 2:1 matched patients
revealed greater need for reoperation for bleeding in the clo-
pidogrel group (5.6% vs 0.5%; P .009) and tendency
toward more transfusion (61.1% vs 51.1%; P ¼ .1). From
all blood products, only fresh frozen plasma transfusion
rates were significantly higher in the clopidogrel group
(P ¼ .02). Other blood products such as red blood cells,
platelets, and cryoprecipitate were similar between the two
matched groups (Figure 1). Median hospitalization lengths
of stay were similar between matched groups.
Mortality by propensity analysis did not differ between
the groups (4.5% in the clopidogrel group and 2.8% in
the controls). However, there was a tendency toward more
major adverse events in the clopidogrel group than in the
control group: 15.9% versus 9.6% (odds ratio 1.792,
95% confidence interval 0.826–3.887; P ¼ .1).
DISCUSSION
Data from several large randomized multicenter trials
have recognized the clinical benefits of dual-antiplatelet
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DTABLE I. Baseline demographics in the two unmatched groups
Overall population
(n ¼ 1104)
Control group
(n ¼ 981)
Clopidogrel group
(n ¼ 123) P value
Age, y 64.3  13.8 64.5  12.9 63  20 .3
Male sex 959 (86.7) 856 (87.2) 103 (83.7) .1
Elective 678 (61.4) 649 (66.1) 29 (23.5) .0001
EuroSCORE 4.02  3.5 3.8  3.3 5.1  4.5 .008
Prior myocardial infarction 446 (40.4) 395 (40.2) 51 (41.4) .7
Prior CABG 44 (3.9) 37 (3.7) 7 (5.7) .3
History of PVD 44 (3.9) 37 (3.7) 7 (5.7) .3
History of carotid disease 56 (5.1) 51 (5.2) 5 (4) .5
History of COPD 34 (2.8) 30 (3.5) 4 (3.5) .8
Hypertension 758 (68.5) 672 (68.5) 86 (69.9) .7
Diabetes mellitus 267 (24.1) 236 (24) 31 (25) .7
Stable angina 172 (18) 159 (18.7) 13 (12.5) .1
Unstable angina 662 (60.5) 618 (63.4) 89 (73) .05
History of heart failure 26 (2.3) 21 (2.1) 5 (4) .1
Hematocrit,% 40.6  4.3 40.9  4.2 38  3 .0005
Creatinine, mg/dl. 1.18  0.4 1.19  0.4 1.11  0.29 .02
Renal failure 38 (3.4) 36 (3.6) 2 (1.6) .2
Ejection fraction<50% 310 (28) 272 (27.2) 38 (30.8) .4
Total number of grafts 3.03  0.8 3.02  0.8 3.05  0.9 .7
LITA 1044 (94.6) 926 (94.4) 117 (95.1) .7
RITA 736 (66.7) 660 (67.3) 86 (69.9) .5
RA 496 (29.5) 285 (29.1) 38 (30.8) .6
SVG 169 (13.4) 138 (14.1) 14 (11.3) .4
Data are presented as numbers (percentages) or means standard deviation. CABG, Coronary artery bypass grafting; PVD, peripheral vascular disease; COPD, chronic obstructive
pulmonary disease; LITA, left internal thoracic artery; RITA, right internal thoracic artery; RA, radial artery; SVG, saphenous vein graft.therapy with aspirin and clopidogrel for patients with acute
coronary syndromes.7-9 Still, some patients require urgent
surgical revascularization and need to be operated on while
on the potent and irreversible platelet inhibition effect ex-
erted by clopidogrel. Under such a scenario, CABG carries
a dramatic increase in bleeding risk. Furthermore, several in-
vestigators have already demonstrated high transfusion and
reoperation rates after on-pump CABG owing to recent clo-
pidogrel use.10-12,22,31,32
OPCABG is a safe technique and reduces bleeding risk
when compared with on-pump surgery.20,22,24 However,
limited data are available regarding the clopidogrel bleeding
risk during OPCABG. In our study, total blood drainage was
similar between groups. Although patients who received
clopidogrel showed a transfusion rate similar to that of the
control group (61.1% vs 51.1%; P ¼ .1), there were more
requirements for fresh frozen plasma units per patient
(18% vs 8%; P ¼ .02). It is possible that a low threshold
for platelet transfusion may have prevented further bleeding
in the clopidogrel group. Nevertheless, reoperation rates
were higher in the clopidogrel group (5.6% vs 0.5%; P ¼
.009). Although postoperative bleeding was similar between
groups, intrathoracic blood and thrombus obtained during
reoperation were not counted.
In concert with our results, a recent study reported expe-
rience in 224 consecutive surgical cases11; 54 of themThe Journal of Thoracic and Creceived clopidogrel within 7 days before the procedure
(clopidogrel group). In that study, the clopidogrel group
had greater blood drainage during the postoperative days
as well as an increased rate of blood transfusions and reop-
erations resulting from bleeding. Differences in study design
between this latter study and ours may explain the differ-
ences in blood drainage.
TABLE II. Postoperative data in the two unmatched groups
Overall
population
(n ¼ 1104)
Control
group
(n ¼ 981)
Clopidogrel
group
(n ¼ 123) P value
Renal dysfunction 22 (1.9) 17 (1.7) 5 (4) .08
Dialysis 8 (0.7) 6 (0.6) 2 (1.6) .2
Postoperative stroke 10 (0.9) 9 (0.9) 1 (0.8) .9
AMV>48 h 39 (3.5) 25 (2.5) 14 (11.3) <.001
Perioperative MI 18 (1.6) 14 (1.4) 4 (3.2) .1
Blood transfusion 518 (47.2) 441 (45.9) 70 (57.7) .02
Bleeding re-exploration 19 (1.7) 14 (1.4) 5 (4) .03
Postoperative blood
loss, mL
846  543 840  537 892  586 .3
Hospital stay,
median, d
5 (4-8) 5 (4-7) 8 (5-10) <.001
MACE 175 (15.85) 166 (17.07) 9 (7.24) .0001
Mortality 33 (2.9) 27 (2.7) 6 (4.8) .1
AMV, Assisted mechanical ventilation; MI, myocardial infarction; MACE, major
adverse cardiovascular events.
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lates into greater postoperative bleeding after on-pump
CABG and OPCABG. In a recent published study by As-
cione and associates,10 the authors demonstrated that admin-
istration of clopidogrel within 48 hours from CABG (62.8
% off-pump) carries a greater risk of death than receiving
clopidogrel within 48 to 120 hours of the procedure. Thus,
the shorter the interval between the last clopidogrel dose
and the surgical procedure, the higher the bleeding risk.
Nevertheless, Kapetanakis and associates33 reported on
1572 patients undergoing only OPCABG. They found no
mortality differences in patients taking clopidogrel preoper-
atively when compared with the controls, whereas morbidity
was worse (prolonged assisted mechanical ventilation time,
higher need for intra-aortic balloon pump use, and develop-
ment of arrhythmias and stroke with no impact on myocar-
dial infarction rate and renal dysfunction). In concordance
with the aforementioned study, we did not observe differ-
ences between the two groups in terms of perioperative myo-
cardial infarction, renal dysfunction, or mortality rates,
whereas the clopidogrel group was associated with a greater
need for postoperative mechanical ventilation. As also
showed by Habib, Anoar, and Engoren,34 we observed
that transfusion rate was a predictor of prolonged mechani-
cal ventilation (odds ratio 2.41; 95% confidence interval
1.48–3.94; P< .0001).
Study Limitations
Although most of the important clinical characteristics
previously known to influence bleeding outcomes were ad-
justed by propensity score, the retrospective design of this
single-center study and the small size of the study population
raise the potential for errors. Nevertheless, data were gath-
ered prospectively in our cardiac surgery database through-
out the study period. It is also possible that subtle differences
in patient care may exist between patients who recently re-
ceived clopidogrel and those who did not. Platelets may
have been administered more liberally to the clopidogrel
group because of expected platelet dysfunction in these pa-
tients. This in turn may have affected bleeding risk and the
amount of blood loss. We did not perform platelet function
studies. Although propensity score helps adjust for differ-
ences between groups, it does not control for unmeasured
differences in patient characteristics and clinical care. In
our population, the use of propensity score may have been
underpowered for the evaluation of differences in bleeding
and transfusion rates between the two groups.
TABLE III. Baseline demographics in the two matched groups
Control group
(n ¼ 176)
Clopidogrel group
(n ¼ 88) P value
Age, y 63.1  19.8 63.2  23.8 .9
Male sex 147 (83.5) 71 (80.6) .5
Prior myocardial infarction 69 (39.2) 42 (47.7) .1
EuroSCORE 4.09  0.3 4.39  0.5 .1
Prior CABG 9 (5.1) 6 (6.8) .5
History of PVD 12 (6.8) 5 (5.6) .7
History of carotid disease 8 (4.5) 5 (5.6) .7
History of COPD 7 (3.9) 3 (3.4) .8
Hypertension 119 (67.5) 62 (70.4) .6
Diabetes mellitus 39 (22.1) 25 (28.4) .2
Unstable angina 123 (69.8) 64 (72.7) .6
History of heart failure 5 (2.8) 2 (2.2) .7
Hematocrit,% 39.5  4.3 39.4  4.8 .8
Creatinine, mg/dL 1.14  0.3 1.12  0.3 .7
Renal failure 6 (3.4) 2 (2.2) .6
EF<50% 53 (30.1) 31 (35.2) .4
Total number of grafts 3.02  0.8 3.01  0.9 .4
LITA 166 (94.7) 83 (94.5) .7
RITA 117 (66.9) 58 (66.5) .9
RA 51 (29.3) 26 (29.7) .9
SVG 24 (13.7) 11 (13.2) .7
Data are presented as numbers (percentages) or means  standard deviation. CABG,
Coronary artery bypass grafting; PVD, peripheral vascular disease;COPD, chronic ob-
structive pulmonary disease; EF, ejection fraction; LITA, left internal thoracic artery;
RITA, right internal thoracic artery; RA, radial artery; SVG, saphenous vein graft.
TABLE IV. Postoperative data in the two matched groups
Control group
(n ¼ 176)
Clopidogrel group
(n ¼ 88) P value
Renal dysfunction 5 (2.8) 3 (3.4) .8
Dialysis 3 (1.7) 2 (2.2) .7
Postoperative stroke 4 (2.2) 1 (1.1) .5
AMV>48 h 7 (4) 9 (10) .045
Perioperative MI 3 (1.7) 3 (3.4) .3
Blood transfusion 88 (50) 53 (60.2) .1
Bleeding re-exploration 1 (0.5) 5 (5.6) .009
Postoperative blood
loss, mL
845  622 910  325 .3
Hospital stay, median, d 7 (5-11) 8 (5-10) .1
MACE 17 (9.6) 14 (15.9) .1
Mortality 5 (2.8) 4 (4.5) .4
AMV, Assisted mechanical ventilation; MI, myocardial infarction; MACE, major
adverse cardiovascular events.
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FIGURE 1. Blood products requirement in the two matched groups (per-
centage of patients with transfusion). PRBC, Packed red blood cells; FFP,
fresh frozen plasma; CRYO, cryoprecipitates.
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This study indicates that clopidogrel administration
within 7 days of OPCABG surgery increases postoperative
morbidity. Preoperative clopidogrel use was associated
with higher rates of reoperation for bleeding, fresh frozen
plasma transfusion, and need for assisted mechanical venti-
lation. There was a tendency toward greater mortality. Early
platelet transfusion during surgery may prevent major post-
operative bleeding. The decision to perform OPCABG
within 7 days of administration of clopidogrel should be
based on balancing the risk of delaying surgery versus the
risk of increased bleeding and morbidity.
References
1. Leon M, Popma J, Gordon P, Cutlip D, Ho K, Giambartolomei A, et al. A clinical
trial comparing three antithrombotic-drug regimens after coronary-artery stenting.
Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:
1665-71.
2. Steinhubl S, Berger P, Man J. Early and sustained dual oral antiplatelet therapy
following percutaneous coronary intervention: a randomized controlled trial.
JAMA. 2002;288:2411-20.
3. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, et al. Effectiveness
of clopidogrel and aspirin in preventing stent thrombosis after coronary stent
implantation. Circulation. 1999;99:2364-6.
4. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and
clopidogrel after intra-coronary stent implantation in a broad patient population.
Circulation. 2001;104:539-43.
5. Stone G, Ellis S, Colombo A, Dawkins K, Cutlip D, Friedman M, et al. Offsetting
impact of thrombosis and restenosis on the occurrence of death and myocardial
infarction after paclitaxel-eluting and bare metal stent implantation. Circulation.
2007;115:2842-7.
6. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al.
TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting
stents in the treatment of complex, long coronary artery lesions from a multicenter,
randomized trial: support for the use of drug-eluting stents in contemporary clin-
ical practice. Circulation. 2005;112:3306-13.
7. Harker L, Boissel J, Pilgrim A, Gent M. Comparative safety and tolerability of
clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee
and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic
events. Drug Saf. 1999;21:325-35.
8. Mehta SR, Yusuf S. Clopidogrel in Unstable angina to prevent Recurrent Events
(CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Re-
current Events (CURE) trial programme; rationale, design and baseline character-
istics including a meta-analysis of the effects of thienopyridines in vascular
disease. Eur Heart J. 2000;21:2033-41.
9. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patient Limited
by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of
the platelets glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and
non–Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-97.
10. Ascione R, Ghosh A, Roger A, Cohen A, Monk C, Angelini G. In hospital patients
exposed to clopidogrel before coronary artery bypass graft surgery: a word of
caution. Ann Thorac Surg. 2005;79:1210-6.
11. Hongo R, Ley J, Dick S, Yee R. The effect of clopidogrel in combination with
aspirin when given before coronary artery bypass surgery. J Am Coll Cardiol.
2002;40:231-7.
12. Chu M, Wilson S, Novick R, Stitt L, Quantaz M. Does clopidogrel increase blood
loss following coronary artery bypass surgery? Ann Thorac Surg. 2004;78:
1536-41.
13. Harper LA. Bleeding after cardiopulmonary bypass. N Engl J Med. 1986;314:
1446-7.
14. Levy JH. Platelet inhibitors and bleeding in cardiac surgical patients. Ann Thorac
Surg. 2000;70:S9-11.
15. Mack M, Bachand D, Acuff T, Edgerton J, Prince S, Dewey T, et al. Improved
outcomes in coronary artery bypass grafting with beating heart techniques.
J Thorac Cardiovasc Surg. 2002;124:598-607.
16. Calafiore AM, Angelini GD, Bergsland J, Salerno TA. Minimally invasive coro-
nary artery bypass grafting. Ann Thorac Surg. 1996;62:1545-8.
17. Nuttall GA, Erchul DT, Haight TA. A comparison of bleeding and transfusion
in patients who undergo coronary artery bypass grafting via sternotomy with
and without cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2003;17:
447-51.
18. Puskas JD, Williams WH, Duke PG, Staples JR, Glas KE, Marshall JJ, et al. Off-
pump coronary artery bypass grafting provides complete revascularization with
reduced myocardial injury, transfusion requirements, and length of stay: a pro-
spective randomized comparison of two hundred unselected patients undergoing
off-pump versus conventional coronary artery bypass grafting. J Thorac Cardio-
vasc Surg. 2003;125:797-808.
19. Subramanian VA. Less invasive arterial CABG on a beating heart. Ann Thorac
Surg. 1997;63:68-71.
20. Vedin J, Antovic A, Ericsson A, Vaage J. Hemostasis in off-pump compared to
on-pump coronary artery bypass grafting: a prospective, randomized study. Ann
Thorac Surg. 2005;80:586-93.
21. Yokoyama T, Baumgartner FJ, Gheissari A, Capouya ER, Panagiotides GP,
Declusin RJ. Off-pump versus on-pump coronary bypass in high-risk subgroups.
Ann Thorac Surg. 2000;70:1546-50.
22. Englberger L, Faeh B, Berdat PA, Eberli F, Meier B, Carrel T. Impact of clopidog-
rel in coronary artery bypass grafting. Eur J Cardiothoracic Surg. 2004;26:
96-101.
23. Mun˜oz JJ, Birkmeyer NJ, Dacey LJ, Birkmeyer JD, Charlesworth DC,
Johnson ER, et al. Trends in rates of reexploration for hemorrhage after coronary
artery bypass surgery. Northern New England Cardiovascular Disease Study
Group. Ann Thorac Surg. 1999;68:1321-5.
24. Ascione R, Williams S, Lloyd CT, Sundaramoorthi T, Pitsis AA, Angelini GD.
Reduced postoperative blood loss and transfusion requirement after beating-heart
coronary operations: a prospective randomized study. J Thorac Cardiovasc Surg.
2001;121:689-96.
25. Shennib H, Endo M, Benhameid O. A feasibility study of the safety and efficacy
of a combined clopidogrel and aspirin regimen following off-pump coronary
artery bypass grafting. Heart Surg Forum. 2003;6:288-91.
26. D’Ancona G, Donias HW, Karamanoukian RL, Bergsland J, Karamanoukian HL.
OPCAB therapy survey: off-pump clopidogrel, aspirin or both therapy survey.
Heart Surg Forum. 2001;4:354-8.
27. Gansera B, Schimdtler F, Spiliopoulos K, Angelis I, Neumaier-Prauser P,
Kenkes BM. Urgent or emergent coronary revascularization using bilateral inter-
nal thoracic artery after previous clopidogrel antiplatelet therapy. Thorac Cardi-
ovasc Surg. 2003;51:185-9.
28. Vrancic JM, Piccinini F, Vaccarino GN, Iparraguirre E, Albertal J, Navia D.
Endoscopic saphenous vein harvesting: initial experience and learning curve.
Ann Thorac Surg. 2000;70:1086-9.
29. Tector AJ, Schmahl TM. Techniques for multiple internal mammary artery bypass
grafts. Ann Thorac Surg. 1984;38:281-6.
30. Austin PC. Propensity-score matching in the cardiovascular surgery literature
from 2004 to 2006: a systematic review and suggestions for improvement.
J Thorac Cardiovasc Surg. 2007;134:1128-35.
31. Gurbuz A, Zia A, Vuran A, Cui H, Aytac A. Postoperative clopidogrel improves
mid-term outcome after off-pump coronary artery bypass graft surgery: a prospec-
tive study. Eur J Cardiothorac Surg. 2006;29:190-5.
32. Chen L, Bracey A, Radovanecevic R, Cooper J, Collard C, Vaughn W, et al.
Clopidogrel and bleeding in patients undergoing elective coronary artery bypass
grafting. J Thorac Cardiovasc Surg. 2004;128:425-31.
33. Kapetanakis E, Medlam D, Petro K, Haile E, Hill P, Dullum M, et al. Effect of
clopidogrel premedication in off-pump cardiac surgery. Are we forfeiting the
benefits of reduced hemorrhagic sequelae? Circulation. 2006;113:1667-74.
34. Habib R, Anoar Z, Engoren M. Determinants of prolonged mechanical ventilation
after coronary artery bypass grafting. Ann Thorac Surg. 1996;62:1164-71.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 2 313
